McCormack Innovation signs significant supply agreement to the Yemen

McCormack Innovation signs significant supply agreement to the Yemen

McCormack Innovation, working alongside strategic partners including the University of Dundee to develop the world’s first soluble medical dressings that will dissolve in seconds when immersed in water, has signed a significant supply agreement to the Yemen. The agreement will see hundreds of thousands of units of soluble medical organisational tape supplied to the country, with the focus of the product in treating malnourished children (for attaching feeding tubes etc). A first of its kind, McCormack Innovation’s soluble medical tape can easily be removed from sensitive or damaged skin without touching the patient or the dressing and thereby greatly reducing patient trauma. The product’s uniqueness rests in its ability to dissolve in water. There are several methods to dissolve the tape; it can be submerged in water for a short period of time where it will detach itself from the skin without any need for abrasion. It can also be removed in the shower or with a fine spray of water and leaves no residue. Brian McCormack, Managing Director, McCormack Innovation said: Having received interest from a leading medical company based in Sana, Yemen for our medical dressings to be delivered to this war-torn country, we were humbled to be able to help in this humanitarian crisis and provided the initial order of 1100 units free of charge.” Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More